Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca
Astex Therapeutics confirmed the commencement of a Phase I study for AZD5363, a Protein Kinase B (PKB, also known as Akt) inhibitor. AZD5363 is a clinical candidate selected in January 2010 by AstraZeneca subsequent to its collaborative programme with Astex. The collaborative programme originated from an earlier Astex collaboration with The Institute of cancer Research (ICR) and Cancer Research Technology Limited (CRT) which began in 2003.
AZD5363 is an orally active selective inhibitor of PKB/Akt, a key enzyme in the PI3K/PKB/mTOR tumour cell survival pathway, and dysregulation of this pathway leads to tumour resistance to a number of important anti-cancer drugs. Inhibition of PKB/Akt has potential in the treatment of a broad range of cancer types.
The Phase I study, being conducted at multiple centres in Europe, is designed to investigate the safety, tolerability and preliminary anti-cancer activity of AZD5363 in patients with advanced solid tumours, and to identify a dose and schedule that can be used in Phase II trials.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

The aging brain: protein mapping furnishes new insights - Researchers at LMU and the SyNergy Cluster of Excellence have analyzed how the proteome of specific brain cells changes as we age

Poor heart health predicts premature brain ageing - Multiple risk factors for a prematurely ageing brain identified

Scientists engineer new potent antibiotic - Darobactin 22 could have the potential to become the next antibiotic superstar
Young's_syndrome
Breakthrough model holds promise for treating Graves' disease - Animal model first to simulate eye complications of thyroid disorder

Many of the deadliest cancers receive the least amount of research funding - 'Embarrassing' or stigmatized cancers like lung and liver are underfunded

Fast-tracking T cell therapies with immune-mimicking biomaterials
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion - Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

Early Prediction of Alzheimer’s Progression in Blood
New marker for Alzheimer's discovered

A nanofiber matrix for healing
